Market Blog

EBIO and XTLY may have bullish sentiments

EBIO - Eleven Biotherapeutics, Inc, a clinical-stage biotech company, hit the bottom after announcing that its investigational eye drop failed as a cure for allergic conjunctivitis. EBIO - Eleven Biotherepeutics, Inc Fundamentals Previously closed at 0.31 Day's high 0.31 Day's low 0.27 P/E ratio NA EPS -1.71   Analyst opinion The recent stock sell-off's seem to have hit the biotech company really hard, with EBIO hitting a new low, losing